US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US5169939A
(en)
|
1985-05-21 |
1992-12-08 |
Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College |
Chimeric antibodies
|
US4720449A
(en)
|
1985-06-03 |
1988-01-19 |
Polaroid Corporation |
Thermal imaging method
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
DK0463151T3
(en)
|
1990-01-12 |
1996-07-01 |
Cell Genesys Inc |
Generation of xenogenic antibodies
|
DK0546073T3
(en)
|
1990-08-29 |
1998-02-02 |
Genpharm Int |
Production and use of transgenic, non-human animals capable of forming heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
AU2515992A
(en)
|
1991-08-20 |
1993-03-16 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
EP0746609A4
(en)
|
1991-12-17 |
1997-12-17 |
Genpharm Int |
Transgenic non-human animals capable of producing heterologous antibodies
|
AU675661B2
(en)
|
1992-07-24 |
1997-02-13 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
DE4228162C1
(en)
|
1992-08-25 |
1994-01-13 |
Rajewsky Klaus Dr |
Method for replacing homologous gene segments from mammals in the germline of non-human mammals
|
JP4242447B2
(en)
|
1993-01-22 |
2009-03-25 |
イミュネックス・コーポレーション |
Detection and treatment of CD40 ligand gene mutations
|
EP0754225A4
(en)
|
1993-04-26 |
2001-01-31 |
Genpharm Int |
Transgenic non-human animals capable of producing heterologous antibodies
|
DE4331162A1
(en)
|
1993-09-14 |
1995-03-16 |
Bayer Ag |
Process for the preparation of cyanine dyes
|
US7119248B1
(en)
|
1994-04-12 |
2006-10-10 |
Miltenyi Biotec Gmbh |
Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
|
US6130364A
(en)
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
WO1997049804A1
(en)
|
1996-06-26 |
1997-12-31 |
Baylor College Of Medicine |
Chromosomal rearrangement by insertion of two recombination substrates
|
DE69738166T2
(en)
|
1996-06-27 |
2008-06-19 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
Antibody molecules that specifically interact with the active site or active site of a target molecule
|
ES2301183T3
(en)
|
1996-12-03 |
2008-06-16 |
Amgen Fremont Inc. |
COMPLETELY HUMAN ANTIBODY THAT JOINS THE EGFR RECEIVER.
|
US6319906B1
(en)
|
1996-12-31 |
2001-11-20 |
Isis Pharmaceuticals |
Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
|
ES2246069T3
(en)
|
1997-05-02 |
2006-02-01 |
Genentech, Inc. |
PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS.
|
US20020088019A1
(en)
|
1997-09-02 |
2002-07-04 |
Oron Yacoby-Zeevi |
Methods of and pharmaceutical compositions for improving implantation of embryos
|
DE69839742D1
(en)
|
1997-11-18 |
2008-08-28 |
Pioneer Hi Bred Int |
Compositions and methods for the genetic modification of plants
|
EP0939120A1
(en)
|
1998-02-27 |
1999-09-01 |
Gesellschaft für biotechnologische Forschung mbH (GBF) |
Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells
|
GB9823930D0
(en)
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
CA2373221A1
(en)
|
1999-05-03 |
2000-11-30 |
Yashwant M. Deo |
Human antibodies to staphylococcus aureus
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
CA2307503A1
(en)
|
2000-05-02 |
2001-11-02 |
Carlos F. Barbas Iii |
Peptides for use as a vaccine or treatment for hiv infection
|
BR0112633A
(en)
|
2000-07-21 |
2003-09-16 |
Us Agriculture |
Method for replacing, translocating and stacking DNA in eukaryotic genomes
|
US6596541B2
(en)
*
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
AU2001297523B2
(en)
|
2000-11-17 |
2007-01-18 |
Sab, Llc |
Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
|
ES2295228T3
(en)
|
2000-11-30 |
2008-04-16 |
Medarex, Inc. |
TRANSGROMIC TRANSCROMOSOMIC ROLLERS FOR THE PREPARATION OF HUMAN ANTIBODIES.
|
JP2005505236A
(en)
|
2000-12-19 |
2005-02-24 |
アルトー バイオサイエンス コーポレイション |
Transgenic animals including humanized immune system
|
EE05724B1
(en)
|
2001-01-05 |
2014-10-15 |
Pfizer Inc. |
Antibodies to insulin-like growth factor I receptor
|
JP2003000243A
(en)
|
2001-06-25 |
2003-01-07 |
Takachika Azuma |
Method for producing mutant
|
FR2827302B1
(en)
|
2001-07-13 |
2003-10-10 |
Genoway |
TRANSGENIC CELL AND ANIMAL MODELING HUMAN ANTIGENIC PRESENTATION AND USES THEREOF
|
US20060199204A1
(en)
|
2001-10-05 |
2006-09-07 |
U.S. Epa |
Genetic testing for male factor infertility
|
US20030108925A1
(en)
|
2001-10-05 |
2003-06-12 |
U.S. Epa |
Genetic testing for male factor infertility
|
ES2645698T3
(en)
*
|
2001-11-30 |
2017-12-07 |
Amgen Fremont Inc. |
Transgenic animals that carry human Ig light chain genes
|
WO2003061363A2
(en)
|
2002-01-17 |
2003-07-31 |
Albert Einstein College Of Medicine Of Yeshiva University |
Mutations caused by activation-induced cytidine deaminase
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
DK2314629T4
(en)
|
2002-07-18 |
2023-02-06 |
Merus Nv |
RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
|
EP1539946A4
(en)
|
2002-09-09 |
2006-03-15 |
California Inst Of Techn |
Methods and compositions for the generation of humanized mice
|
US7700356B2
(en)
|
2002-11-08 |
2010-04-20 |
The United States Of America As Represented By The Secretary Of Agriculture |
System for gene targeting and producing stable genomic transgene insertions
|
DE10251918A1
(en)
|
2002-11-08 |
2004-05-19 |
Horn, Carsten, Dipl.-Biochem. Dr. |
Inheritable integration of DNA into germ-line invertebrate cells, useful for large-scale production of transgenic insects, includes post-transformational removal of mobilizable elements to increase stability
|
AR042145A1
(en)
|
2002-11-27 |
2005-06-08 |
Dow Agrociences Llc |
IMMUNOGLOBULIN PRODUCTION IN PLANTS WITH A REDUCED FUCOCILATION
|
GB2398784B
(en)
|
2003-02-26 |
2005-07-27 |
Babraham Inst |
Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
ES2408582T3
(en)
|
2003-05-30 |
2013-06-21 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
WO2005001087A2
(en)
|
2003-06-11 |
2005-01-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying genes in eukaryotic cells
|
GB2403475B
(en)
|
2003-07-01 |
2008-02-06 |
Oxitec Ltd |
Stable integrands
|
US7663017B2
(en)
|
2003-07-30 |
2010-02-16 |
Institut Pasteur |
Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
|
WO2005019463A1
(en)
|
2003-08-11 |
2005-03-03 |
Therapeutic Human Polyclonals, Inc. |
Improved transgenesis with humanized immunoglobulin loci
|
US7604994B2
(en)
|
2003-09-03 |
2009-10-20 |
Morphotek, Inc. |
Genetically altered antibody-producing cell lines with improved antibody characteristics
|
CA2445602C
(en)
|
2003-10-20 |
2014-01-14 |
Campusgen Gmbh |
Nucleotide sequence for creatinine deiminase and method of use
|
HUE025328T2
(en)
|
2003-12-10 |
2016-03-29 |
Squibb & Sons Llc |
IP-10 antibodies and their uses
|
JP2008507257A
(en)
|
2004-03-19 |
2008-03-13 |
アムゲン・インコーポレーテッド |
Reduced risk of human anti-human antibodies through manipulation of V genes
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
JP2008512987A
(en)
|
2004-07-22 |
2008-05-01 |
エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム |
Binding molecule
|
FR2875239B1
(en)
|
2004-09-10 |
2007-07-20 |
Inst Necker Ass Loi De 1901 |
METHOD FOR THE ACCELERATION OF SOMATIC MUTATIONS AND ITS APPLICATION IN PROTEOMICS
|
WO2006029459A1
(en)
|
2004-09-13 |
2006-03-23 |
Evogenix, Inc |
Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
|
WO2006044492A2
(en)
|
2004-10-14 |
2006-04-27 |
Ingenious Targeting Laboratory, Inc. |
Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
|
CA2583750C
(en)
|
2004-10-19 |
2015-11-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for generating a rodent having a genetic modification
|
WO2006055704A2
(en)
|
2004-11-17 |
2006-05-26 |
Curagen Corporation |
Antibodies directed to ten-m proteins and uses thereof
|
US7973140B2
(en)
|
2004-12-21 |
2011-07-05 |
Medimmune Limited |
Antibodies directed to angiopoietin-2 and uses thereof
|
WO2006117699A2
(en)
|
2005-04-29 |
2006-11-09 |
Innate Pharma |
Transgenic animals and methods of making recombinant antibodies
|
WO2006122442A1
(en)
|
2005-05-14 |
2006-11-23 |
Fudan University |
Piggybac as a tool for genetic manipulation and analysis in vertebrates
|
EP1780272A1
(en)
|
2005-10-27 |
2007-05-02 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Method for enhancing somatic hypermutation, gene conversion and class switch recombination
|
GB0601513D0
(en)
|
2006-01-25 |
2006-03-08 |
Univ Erasmus Medical Ct |
Binding molecules 3
|
KR101481843B1
(en)
|
2006-01-25 |
2015-01-12 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
Generation of heavy-chain only antibodies in transgenic animals
|
US7462759B2
(en)
|
2006-02-03 |
2008-12-09 |
Pioneer Hi-Bred International, Inc. |
Brittle stalk 2 gene family and related methods and uses
|
JP5514539B2
(en)
|
2006-03-31 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
US7582298B2
(en)
|
2006-06-02 |
2009-09-01 |
Regeneron Pharmaceuticals, Inc. |
High affinity antibodies to human IL-6 receptor
|
WO2008094178A2
(en)
|
2006-06-27 |
2008-08-07 |
Vaxdesign Corporation |
Models for vaccine assessment
|
EP1878342A1
(en)
|
2006-07-13 |
2008-01-16 |
Institut Pasteur |
Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
|
EP2061812A4
(en)
|
2006-08-22 |
2010-06-09 |
G2 Inflammation Pty Ltd |
Method for producing antibodies
|
HUE054090T2
(en)
|
2006-10-02 |
2021-08-30 |
Regeneron Pharma |
High affinity human antibodies to human il-4 receptor
|
WO2008070367A2
(en)
|
2006-11-01 |
2008-06-12 |
Facet Biotech Corporation |
Mammalian cell-based immunoglobulin display libraries
|
RU2448979C2
(en)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Human antibodies to delta-like human ligand-4
|
GB0700194D0
(en)
|
2007-01-05 |
2007-02-14 |
Univ Edinburgh |
Humanisation of animals
|
WO2008103475A1
(en)
|
2007-02-20 |
2008-08-28 |
Anaptysbio, Inc. |
Somatic hypermutation systems
|
PT2125889E
(en)
|
2007-02-21 |
2014-04-15 |
Univ Massachusetts |
Human antibodies against hepatitis c virus (hcv) uses thereof
|
BRPI0809435A2
(en)
|
2007-03-27 |
2014-09-09 |
Sea Lane Biotechnologies Llc |
CONSTRUCTS AND LIBRARIES UNDERSTANDING ANTIBODY SUBSTITUTED LIGHT CHAIN SEQUENCES
|
GB0706628D0
(en)
|
2007-04-04 |
2007-05-16 |
Univ Erasmus |
Germ-line manipulation 1
|
EP3382022A1
(en)
|
2007-06-01 |
2018-10-03 |
Open Monoclonal Technology, Inc. |
Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
|
WO2009013620A2
(en)
|
2007-06-11 |
2009-01-29 |
Erasmus University Medical Center Rotterdam |
Homologous recombination
|
ES2527297T3
(en)
|
2007-07-31 |
2015-01-22 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies for human CD20 and method to use them
|
CN101827609B
(en)
|
2007-08-10 |
2014-03-12 |
里珍纳龙药品有限公司 |
High affinity human antibodies to human nerve growth factor
|
JP5588866B2
(en)
|
2007-08-10 |
2014-09-10 |
メダレックス エル.エル.シー. |
HCO 32 and HCO 27 and related examples
|
US8771988B2
(en)
|
2007-10-12 |
2014-07-08 |
Hoffmann-La Roche Inc. |
Protein expression from multiple nucleic acids
|
EP2245155A4
(en)
|
2007-12-10 |
2011-05-25 |
Aliva Biopharmaceuticals Inc |
Methods for sequential replacement of targeted region by homologous recombination
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
CA2718517A1
(en)
|
2008-03-26 |
2009-10-01 |
Iti Scotland Limited |
Efficient insertion of dna into embryonic stem cells
|
EP2271758B1
(en)
|
2008-04-14 |
2018-09-12 |
Innovative Targeting Solutions Inc. |
Sequence diversity generation in immunoglobulins
|
KR20110020860A
(en)
|
2008-05-23 |
2011-03-03 |
알리바 바이오파마수티컬스, 아이엔씨. |
Method of generating single vl domain antibodies in transgenic animals
|
PT2147594E
(en)
|
2008-06-27 |
2014-02-17 |
Merus B V |
Antibody producing non-human mammals
|
EP3889265A1
(en)
|
2008-09-30 |
2021-10-06 |
Ablexis, LLC |
Transgenic mice for the production of chimeric antibodies
|
JO3672B1
(en)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
High Affinity Human Antibodies to PCSK9
|
CN112626117A
(en)
|
2008-12-18 |
2021-04-09 |
伊拉兹马斯大学鹿特丹医学中心 |
Non-human transgenic animals expressing humanized antibodies and uses thereof
|
US9085795B2
(en)
|
2009-02-04 |
2015-07-21 |
Molecular Innovations, Inc. |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
|
CA2753287A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
EP2414507B1
(en)
|
2009-04-03 |
2014-07-02 |
Medical Research Council |
Mutants of activation-induced cytidine deaminase (aid) and methods of use
|
TWI560271B
(en)
|
2009-06-26 |
2016-12-01 |
Sealane Biotechnologies Llc |
Expression of surrogate light chains
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP2564695B1
(en)
|
2009-07-08 |
2015-04-15 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
CA2768207C
(en)
|
2009-07-15 |
2019-12-03 |
Aimm Therapeutics B.V. |
Means and methods for producing high affinity antibodies
|
JO3182B1
(en)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
High Affinity Human Antibodies to Human Angiopoietin-2
|
WO2011019844A1
(en)
|
2009-08-13 |
2011-02-17 |
Crystal Bioscience Inc. |
Transgenic animal for production of antibodies having minimal cdrs
|
WO2011047146A2
(en)
*
|
2009-10-14 |
2011-04-21 |
Centocor Ortho Biotech Inc. |
Methods of affinity maturing antibodies
|
EP2496706A4
(en)
|
2009-11-05 |
2013-07-17 |
Anaptysbio Inc |
Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation
|
CN102741404B
(en)
|
2009-11-17 |
2017-03-08 |
Sab有限责任公司 |
human artificial chromosome vector
|
US20120269830A1
(en)
|
2009-12-07 |
2012-10-25 |
Lawrence Horowitz |
Conjugates with improved pharmacokinetic properties
|
HUE030208T2
(en)
|
2009-12-10 |
2017-04-28 |
Regeneron Pharma |
Mice that make heavy chain antibodies
|
EP2501817B2
(en)
|
2010-02-08 |
2021-04-21 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
EP3156062A1
(en)
|
2010-05-17 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
CN103228130B
(en)
*
|
2010-06-17 |
2016-03-16 |
科马布有限公司 |
Animal model and treatment molecule
|
CN103068993B
(en)
|
2010-06-22 |
2016-01-06 |
瑞泽恩制药公司 |
Hybrid light chain mice
|
KR20210129278A
(en)
*
|
2010-07-16 |
2021-10-27 |
아디맵 엘엘씨 |
Abtibody libraries
|
ES2612459T3
(en)
|
2010-08-02 |
2017-05-17 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce binding proteins that comprise VL domains
|
CN103261220B
(en)
|
2010-08-16 |
2016-06-15 |
诺夫免疫股份有限公司 |
For generating the method for polyspecific and multivalent antibody
|
JO3375B1
(en)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
Human antibodies to human tnf-like ligand 1a (tl1a)
|
AR084456A1
(en)
|
2010-12-22 |
2013-05-15 |
Genentech Inc |
ANTI-PCSK9 ANTIBODY AND METHODS OF USE
|
SG10201913160QA
(en)
|
2011-02-25 |
2020-03-30 |
Regeneron Pharma |
Adam6 mice
|
NZ781020A
(en)
|
2011-08-05 |
2023-01-27 |
Regeneron Pharma |
Humanized universal light chain mice
|
CN106995822B
(en)
|
2011-09-19 |
2021-06-29 |
科马布有限公司 |
Antibodies, variable domains and chains tailored for human use
|
JP2014531452A
(en)
|
2011-09-19 |
2014-11-27 |
カイマブ・リミテッド |
Animals, repertoire and methods
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
HUE057680T2
(en)
|
2011-10-17 |
2022-06-28 |
Regeneron Pharma |
Restricted immunoglobulin heavy chain mice
|
US20130102031A1
(en)
|
2011-10-25 |
2013-04-25 |
Anaptysbio, Inc. |
Use of somatic hypermutation to create insertion and deletion mutations in vitro
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
GB201122047D0
(en)
*
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
US20180295821A1
(en)
|
2011-12-02 |
2018-10-18 |
Kymab Limited |
Transgenic Animals
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
KR102186822B1
(en)
|
2011-12-20 |
2020-12-04 |
리제너론 파마슈티칼스 인코포레이티드 |
Humanized light chain mice
|
CA2863175A1
(en)
|
2012-02-01 |
2013-08-08 |
Regeneron Pharamaceuticals, Inc. |
Humanized rodents that express heavy chains containing vl domains
|
NZ628943A
(en)
|
2012-03-02 |
2016-08-26 |
Regeneron Pharma |
Human antibodies to clostridium difficile toxins
|
RU2683514C2
(en)
*
|
2012-03-06 |
2019-03-28 |
Регенерон Фармасьютикалз, Инк. |
Common light chain mouse
|
EP2825035A1
(en)
|
2012-03-16 |
2015-01-21 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
JP2015512635A
(en)
|
2012-03-28 |
2015-04-30 |
カイマブ・リミテッド |
Transgenic non-human vertebrates for expression of class-switched fully human antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
JO3820B1
(en)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
Human antibodies to fel d1 and methods of use thereof
|
ES2728782T3
(en)
|
2012-05-25 |
2019-10-28 |
Univ California |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation
|
RS62121B1
(en)
|
2012-06-12 |
2021-08-31 |
Regeneron Pharma |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
US8962913B2
(en)
|
2012-06-18 |
2015-02-24 |
Regeneron Pharmaceuticals, Inc. |
Humanized IL-7 rodents
|
DK3327127T3
(en)
|
2012-12-12 |
2021-06-28 |
Broad Inst Inc |
PERFORMANCE, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS
|
BR112015019350A2
(en)
|
2013-02-20 |
2017-08-22 |
Regeneron Pharma |
NON-HUMAN ANIMAL, IMMUNOGLOBULIN LOCUS, AND METHODS OF MANUFACTURING A NON-HUMAN ANIMAL, FOR OBTAINING A NUCLEIC ACID SEQUENCE AND MANUFACTURING AN ANTIGEN-BINDING PROTEIN
|
WO2014141192A1
(en)
|
2013-03-15 |
2014-09-18 |
Erasmus University Medical Center |
Generation of heavy chain-only antibodies
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20150033372A1
(en)
|
2013-05-01 |
2015-01-29 |
Kymab Limited |
Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US20140331344A1
(en)
|
2013-05-03 |
2014-11-06 |
Kymab Ltd. |
Transgenic Animals
|
US20140331339A1
(en)
|
2013-05-03 |
2014-11-06 |
Kymab Limited |
Transgenic Non-Human Assay Vertebrates, Assays and Kits
|
NL2013554B1
(en)
|
2013-10-01 |
2016-01-08 |
Kymab Ltd |
Animal models and therapeutic molecules.
|
GB201710984D0
(en)
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|